Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial

María Inés Figueroa, Omar Sued, Carina Cesar, Patricia Patterson, Cleyton Yamamoto, Valeria Fink, Norma Luna, Antonio Camiro-Zúñiga, Ana Gun, Pedro Cahn
doi: https://doi.org/10.1101/2022.07.08.22277426

Article Information

doi 
https://doi.org/10.1101/2022.07.08.22277426
History 
  • July 9, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. María Inés Figueroa1,*,
  2. Omar Sued1,
  3. Carina Cesar1,
  4. Patricia Patterson1,
  5. Cleyton Yamamoto1,
  6. Valeria Fink1,
  7. Norma Luna2,
  8. Antonio Camiro-Zúñiga3,
  9. Ana Gun1 and
  10. Pedro Cahn1
  1. 1Fundación Huésped, Ciudad Autónoma de Buenos Aires, Argentina
  2. 2Hospital Rawson, Córdoba, Argentina
  3. 3Centro Médico ABC, Mexico City, Mexico
  1. ↵*Corresponding author:
    María Inés Figueroa, Carlos Gianantonio 3932, Ciudad Autónoma de Buenos Aires, C1202ABB, Argentina, +54 11 49811855/7777, maria.figueroa{at}huesped.org.ar
Back to top
Posted July 09, 2022.
Download PDF
Data/Code
Email
Dual therapy with Atazanavir/ritonavir plus Raltegravir versus triple therapy with Atazanavir/ritonavir plus Tenofovir-Emtricitabine after failure to an NNRTI regimen: 48-week results of the randomized pilot study ARTE trial
María Inés Figueroa, Omar Sued, Carina Cesar, Patricia Patterson, Cleyton Yamamoto, Valeria Fink, Norma Luna, Antonio Camiro-Zúñiga, Ana Gun, Pedro Cahn
medRxiv 2022.07.08.22277426; doi: https://doi.org/10.1101/2022.07.08.22277426
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area